Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122434 | 0.82 | ESR1 (0.46) | CA2CA4CA5ATSHRALOX15 | |
| SCHEMBL191567 | 0.78 | CA2 (0.68) | CA2CA4CA5ACFTRTSHR | |
| SCHEMBL9001510 | 0.77 | NPSR1 (0.43) | CA2CA4CA5ACFTRTSHR | |
| SCHEMBL6364549 | 0.76 | ESR1 (0.42) | CA2CA4CA5AESR1ESR2 | |
| SCHEMBL190541 | 0.76 | CA2 (0.65) | CA2CA4CA5ACFTRTSHR | |
| SCHEMBL672826 | 0.76 | CA2 (0.65) | CA2CA4CA5ACFTRTSHR | |
| Hydrochloric Acid SCHEMBL2361106 | 0.76 | CA2 (0.65) | CA2CA4CA5ACFTRTSHR | |
| SCHEMBL19809604 | 0.76 | CA2 (0.65) | CA2CA4CA5ACFTRTSHR | |
| SCHEMBL191417 | 0.76 | CA2 (0.65) | CA2CA4CA5ACFTRTSHR | |
| SCHEMBL19809603 | 0.76 | CA2 (0.65) | CA2CA4CA5ACFTRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0830136-B1 | NEW CRYPTOPHYCINS FROM SYNTHESIS | UNIV HAWAII (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20020128185-A1 | Pharmaceutical compounds | HAWAII, UNIVERSITY OF | 2002-09-12 | — | — | US | disclosed |
| US-6180679-B1 | PARASITICIDE | ELI LILLY AND COMPANY | 2001-01-30 | — | — | US | disclosed |
| EP-0830136-A4 | NEW CRYPTOPHYCINS FROM SYNTHESIS | UNIV HAWAII (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6013626-A | TO INHIBIT THE PROLIFERATION OF MAMMALIAN CELLS; ANTITUMOR AGENTS | THE UNIVERSITY OF HAWAII (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1998046193-A2 | SYNERGISTIC METHOD FOR TREATING A NEOPLASM | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046581-A1 | SYNERGISTIC METHOD FOR TREATING CANCER | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046221-A1 | METHOD FOR TREATING FUNGAL INFECTIONS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0870506-A1 | Compositions comprising a cryptophycin compound in combination with a synchronizing or activating agent for treating cancer | ELI LILLY AND COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0870510-A2 | Synergistic combination comprising cryptophycin derivatives and microtubule synergizing agents | ELI LILLY AND COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0870501-A1 | Use of specific cryptophycin derivatives for the manufacture of a medicament in the treatment of fungal infections | ELI LILLY AND COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0830136-A1 | NEW CRYPTOPHYCINS FROM SYNTHESIS | UNIVERSITY OF HAWAII (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1996040184-A1 | NEW CRYPTOPHYCINS FROM SYNTHESIS | UNIVERSITY OF HAWAII (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128185-A1 | Pharmaceutical compounds | XPO5, XPOT, XPO1 | CA2 1454/4885CA4 625/4885CA5A 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.